1-(4-fluorophenyl)-5-methyl-1H-pyrazol-3-amine | 1247053-40-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-(4-fluorophenyl)-5-methyl-1H-pyrazol-3-amine
• 英文别名: 1-(4-fluorophenyl)-5-methylpyrazol-3-amine
• CAS: 1247053-40-2
• 化学式: C₁₀H₁₀FN₃
• mdl: MFCD11878528
• 分子量: 191.2
• InChiKey: KVTPQQWGYTVBMR-UHFFFAOYSA-N

物化性质

• 沸点：
  326.9±32.0 °C(Predicted)
• 密度：
  1.26±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  43.8
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• [EN] PYRAZOLE DERIVATIVES<br/>[FR] DÉRIVÉS DE PYRAZOLE
  申请人：HUA MEDICINE (SHANGHAI) LTD

  公开号：WO2017117708A1

  公开（公告）日：2017-07-13

  Provided herein are compounds of the formula I: as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment or prevention of mGluR5 mediated disorders, such as acute and/or chronic neurological disorders, cognitive disorders and memory deficits, as well as acute and chronic pain.

  本文提供了公式I的化合物，以及其药学上可接受的盐，其中取代基如规范中所披露的那样。这些化合物及含有它们的药物组合物对于治疗或预防mGluR5介导的疾病非常有用，例如急性和/或慢性神经系统疾病、认知障碍和记忆缺陷，以及急性和慢性疼痛。
• Pyrazole derivatives
  申请人：HUA MEDICINE (SHANGHAI) Ltd.

  公开号：US10941132B2

  公开（公告）日：2021-03-09

  Provided herein are compounds of the formula I: as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment or prevention of mGluR5 mediated disorders, such as acute and/or chronic neurological disorders, cognitive disorders and memory deficits, as well as acute and chronic pain.

  本文提供了式 I：化合物及其药学上可接受的盐类，其中取代基与说明书中公开的取代基相同。这些化合物以及含有它们的药物组合物可用于治疗或预防 mGluR5 介导的疾病，如急性和/或慢性神经系统疾病、认知障碍和记忆缺陷，以及急性和慢性疼痛。
• PYRAZOLE DERIVATIVES
  申请人：HUA MEDICINE (SHANGHAI) Ltd.

  公开号：US20190002432A1

  公开（公告）日：2019-01-03

  Provided herein are compounds of the formula I: as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment or prevention of mGluR5 mediated disorders, such as acute and/or chronic neurological disorders, cognitive disorders and memory deficits, as well as acute and chronic pain.
• [EN] PYRAZOLE COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES<br/>[FR] COMPOSÉ PYRAZOLIQUE ET SON UTILISATION À DES FINS MÉDICALES
  申请人：JAPAN TOBACCO INC

  公开号：WO2013031922A1

  公开（公告）日：2013-03-07

  　下記一般式［Ｉｂ］で示される化合物又はその医薬上許容される塩：［式中、各記号は明細書に記載の通りである。］